Immunome Inc (IMNM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Immunome Inc (IMNM) has a cash flow conversion efficiency ratio of -0.117x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-61.69 Million) by net assets ($525.08 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Immunome Inc (IMNM) total market value for the company's overall valuation and market capitalisation.
Immunome Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Immunome Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Immunome Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immunome Inc ranked by their cash flow conversion efficiency. See Immunome Inc debt service capacity to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PUMA SE
XETRA:PUM
|
-0.249x |
|
Acadia Realty Trust
NYSE:AKR
|
0.022x |
|
ChengDu Hi-Tech Development Co Ltd
SHE:000628
|
0.041x |
|
Grindr Inc
NYSE:GRND
|
-3.476x |
|
Hainan Mining Co Ltd
SHG:601969
|
0.046x |
|
Shenzhen Gas Corp Ltd
SHG:601139
|
0.053x |
|
Fuchs Petrolub SE
XETRA:FPE
|
0.013x |
|
Turkiye Sigorta AS
IS:TURSG
|
0.034x |
Annual Cash Flow Conversion Efficiency for Immunome Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Immunome Inc from 2018 to 2025. View Immunome Inc (IMNM) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $634.34 Million | $-190.92 Million | -0.301x | +50.79% |
| 2024-12-31 | $181.16 Million | $-110.79 Million | -0.612x | -868.76% |
| 2023-12-31 | $119.88 Million | $-7.57 Million | -0.063x | +96.34% |
| 2022-12-31 | $16.65 Million | $-28.69 Million | -1.723x | -355.47% |
| 2021-12-31 | $48.19 Million | $-18.23 Million | -0.378x | -28.88% |
| 2020-12-31 | $41.34 Million | $-12.13 Million | -0.293x | -208.92% |
| 2019-12-31 | $-35.63 Million | $-9.60 Million | 0.269x | -8.30% |
| 2018-12-31 | $-25.20 Million | $-7.41 Million | 0.294x | -- |
About Immunome Inc
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine… Read more